Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
176 hedge funds and large institutions have $278M invested in Sage Therapeutics in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 52 increasing their positions, 58 reducing their positions, and 24 closing their positions.
150% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $1.1M
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
1% more funds holding
Funds holding: 175 → 176 (+1)
0.5% less ownership
Funds ownership: 84.24% → 83.74% (-0.5%)
10% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 58
26% less capital invested
Capital invested by funds: $374M → $278M (-$95.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$23.1M |
| 2 |
CP
Caligan Partners
New York
|
+$18.7M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$8.49M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$15.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10.1M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$7.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.06M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.64M |
SAGE Hedge Fund Activity: Q4 2024 in Review
176 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2024, worth a combined $278M — down 26% from $374M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SAGE positions and 24 closed out — a net gain of 1 holder — while 52 added to existing stakes and 58 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $23.1M. The largest seller was RTW Investments, cutting an estimated $15.8M.
- 176 institutional investors held Sage Therapeutics (SAGE) as of Q4 2024, up from 175 in Q3 2024.
- Funds reported $278M of Sage Therapeutics stock for Q4 2024, down 26% quarter-over-quarter.
- 25 funds opened new Sage Therapeutics positions in Q4 2024 and 24 closed out, a net change of +1 holder.
- The largest Sage Therapeutics buyer in Q4 2024 was Morgan Stanley, an estimated $23.1M added.
- The largest Sage Therapeutics seller in Q4 2024 was RTW Investments, an estimated $15.8M sold.
Based on aggregated 13F filings for Q4 2024.